{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T06:11:08Z","timestamp":1771567868292,"version":"3.50.1"},"reference-count":9,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,24]],"date-time":"2023-01-24T00:00:00Z","timestamp":1674518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018046","name":"Nippon Kayaku","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018046","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lung-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lung Cancer"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.cllc.2023.01.008","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T20:42:39Z","timestamp":1675197759000},"page":"371-375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["A Phase I\/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non\u2013Small Cell Lung Cancer Study: (NEJ048A\/NEXUS)"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2026-9181","authenticated-orcid":false,"given":"Akihiko","family":"Miyanaga","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Asahina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Shukuya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Tsubata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukio","family":"Hosomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunichi","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Maemondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Okano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kotone","family":"Matsuyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Seike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cllc.2023.01.008_bib0001","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1111\/j.1349-7006.2011.01887.x","article-title":"Efficacy of gefitinib for non-adenocarcinoma non-small-cell lung cancer patients harboring epidermal growth factor receptor mutations: a pooled analysis of published reports","volume":"102","author":"Shukuya","year":"2011","journal-title":"Cancer sci"},{"key":"10.1016\/j.cllc.2023.01.008_bib0002","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1093\/jjco\/hyt056","article-title":"Phase II trial of erlotinib for Japanese patients with previously treated non-small-cell lung cancer harboring EGFR mutations: results of Lung Oncology Group in Kyushu (LOGiK0803)","volume":"43","author":"Yamada","year":"2013","journal-title":"Japn J Clin Oncol"},{"key":"10.1016\/j.cllc.2023.01.008_bib0003","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non\u2013small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"The New Engl J Med"},{"key":"10.1016\/j.cllc.2023.01.008_bib0004","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/S1470-2045(21)00136-4","article-title":"Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial","volume":"22","author":"Sacco","year":"2021","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.01.008_bib0005","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.lungcan.2019.08.009","article-title":"A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer","volume":"136","author":"Villaruz","year":"2019","journal-title":"Lung cancer (Amst, Neth)"},{"key":"10.1016\/j.cllc.2023.01.008_bib0006","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(15)00021-2","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial","volume":"16","author":"Thatcher","year":"2015","journal-title":"The Lancet Oncol"},{"key":"10.1016\/j.cllc.2023.01.008_bib0007","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.lungcan.2019.01.005","article-title":"Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan","volume":"129","author":"Watanabe","year":"2019","journal-title":"Lung cancer (Amst, Neth)"},{"key":"10.1016\/j.cllc.2023.01.008_bib0008","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1158\/2326-6066.CIR-18-0193","article-title":"A high-throughput immune-oncology screen identifies EGFR inhibitors as potent enhancers of antigen-specific cytotoxic T-lymphocyte tumor cell killing","volume":"6","author":"Lizotte","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.cllc.2023.01.008_bib0009","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1158\/1078-0432.CCR-12-2426","article-title":"Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients","volume":"19","author":"Srivastava","year":"2013","journal-title":"Clin Cancer Res: Off J Am Assoc Cancer Res"}],"container-title":["Clinical Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000104?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525730423000104?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T19:14:25Z","timestamp":1761506065000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525730423000104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":9,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["S1525730423000104"],"URL":"https:\/\/doi.org\/10.1016\/j.cllc.2023.01.008","relation":{},"ISSN":["1525-7304"],"issn-type":[{"value":"1525-7304","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase I\/II Study of Necitumumab Plus Pembrolizumab, Nab-Paclitaxel, and Carboplatin for Previously Untreated Advanced Squamous Non\u2013Small Cell Lung Cancer Study: (NEJ048A\/NEXUS)","name":"articletitle","label":"Article Title"},{"value":"Clinical Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cllc.2023.01.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}